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A mass immunization campaign for 18-month to 19-year-olds
was undertaken in Spain in 1996–1997 because of an epidemic
of serogroup C meningococcal disease associated with a
C:2b:P1.2,5 strain belonging to the A4 lineage. Surveillance for
the “capsule-switching” phenomenon producing B:2b:P1.2,5
isolates was undertaken. Of 2,975 meningococci character-
ized, B:2b:P1.2,5 and B:2b:P1.2 antigenic combinations were
found in 18 isolates; 15 meningococci were defined as sero-
group B belonging to the A4 lineage.
n the early 1990s, an increasing number of serogroup C
meningococcal strains were observed in Spain (1). Besides
a change in the predominant serogroup, an increase in the inci-
dence of the meningococcal disease associated with a new
variant of serogroup C (2) was detected. These strains were
characterized as C:2b:P1.2,5. Their frequency in serogroup C
meningococci in Spain increased from 4.6% in 1993 to 65% in
1996 (2). Meningococcal strains characterized as C:2b:P1.2,5
have been described in other countries (3), but they have not
been associated with a similar epidemiologic change. How-
ever, C:2a:P1.2 isolates belonging to the ET15 lineage have
been responsible for epidemic waves in the Czech Republic
and Canada (4,5).
As a result of the increase in such isolates in Spain, a mass
immunization campaign focused at 18-month to 19-year-olds
was conducted with the polysaccharide A+C vaccine in most
of the country in 1996–1997 (6). Three years later, a new C
conjugate vaccine was licensed in Spain. This vaccine was
routinely introduced in autumn 2000 because an increase in
the incidence of serogroup C cases was again detected.
By contrast, B:2b meningococci, which were frequently
isolated during a previous epidemic period in Spain (7), repre-
sented 1.9% of the serogroup B strains characterized in our
laboratory from 1990 to 1992 (8); none of them showed P1.2,5
serosubtype antigenic combinations. From 1995 to autumn
2000 we characterized 18 meningococcal strains as B:2b (14
as B:2b:P1.2,5 and 4 as B:2b:P1.2 isolates). Recombinant
strains expressing serogroup B or C have been previously
described as result of capsule-switching genetic mechanism
(9,10). The aim of our study was to characterize those new
B:2b meningococci variants. We used molecular typing meth-
ods (pulsed-field gel electrophoresis [PFGE] and multilocus
sequence typing [MLST]) to determine the relationships
among B:2b with the parental C:2b:P1.2,5 epidemic strain
before and after the immunization campaign with the A+C
polysaccharide vaccine. 
The Study
The Spanish Reference Laboratory for Meningococci rou-
tinely receives meningococci isolated from sterile sites for
serogrouping, serotyping, and serosubtyping. From January
1995 to November 2000 (just before the new C conjugate vac-
cine was routinely introduced), the laboratory received 2,975
meningococcal strains to be characterized by serotyping and
serosubtyping with monoclonal antibodies (8). The
B:2b:P1.2,5 and B:2b:P1.2 antigenic combinations were found
in 18 isolates (Table 1). All these strains were suspected of
belonging to the A4 lineage and were fully characterized by
PFGE and MLST as described previously (2,11); results were
compared with those obtained among the C:2b:P1.2,5 epi-
demic strains. Two additional strains characterized as
B:4:P1.2,5 were also included to determine if these antigenic
combinations might be caused by similar genetics events.
Conclusions
Fifteen (83.3%) meningococci showed sequence types
identified as representative of the A4 clonal lineage; this lin-
eage also represents the genotype of the C:2b:P1.2,5 epidemic
strain. The proportions of isolates belonging to the A4 clonal
lineage were 75% and 85%, respectively, in both B:2b:P1.2
and B:2b:P1.2,5 strains. Seven of these 15 meningococci char-
acterized as serogroup B belonging to the A4 lineage were iso-
lated from patients who had never been immunized with the
A+C polysaccharide vaccine. Three group B strains that were
suspected by antigenic characterization of belonging to the A4
complex showed nonrelated sequence types (Table 1).
In a different study (data not shown), most of the
C:2b:P1.2,5 epidemic strains grouped in two closely related
pattern profiles by PFGE: PT7 and PT8. Table 1 shows the
PFGE pattern profiles of the B:2b:P1.2,5 strains. Most of these
isolates also showed the PT7 or the PT8 profile. Some strains
showed minor pattern profiles already present among
C:2b:P1.2,5 isolates (PT1, PT4, and PT38, all of them closely
related to PT7 and PT8). Those strains showing PFGE pattern
profiles that we did not find among the C:2b:P1.2,5 epidemic
strain belonged to lineages different than A4 (Table 1). On the
other hand, the B:4:P1.2,5 strains showed the same sequence
type, ST33, associated with ET5.
The frequency of the C:2b:P1.2,5 and B:2b:P1.2,5 menin-
gococci of the A4 lineage is shown in Table 2. A slight
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increase of that group B isolates was found after the immuni-
zation campaign. 
Recombinant strains expressing serogroup B or C have
been previously described as resulting from a capsule-switch-
ing genetic mechanism (9,10). A similar event with W135 iso-
lates has been recently described (12). Thus, all the serogroups
should be capable of changing to any other. However, the rele-
vance of this phenomenon has not been fully described. In our
surveillance analysis, the group B strains of the A4 lineage
appeared before the vaccination campaigns; this finding dif-
fers from results of an analysis conducted in Canada after a
similar surveillance (10). Our findings show that those genetic
variants are being produced in the meningococcal population
at random and that a variant’s appearance is not necessarily
related to mass immunization campaigns. In fact, these group
B meningococci belonging to the A4 lineage were also iso-
lated in some of the regions that used the vaccine on a small
scale (13). 
However, the increased number of these B:2b:P1.2,5
strains from the A4 lineage during the study period might indi-
cate a positive selection caused by mass immunization cam-
paigns during 1996 and 1997 (Table 2). Seven (50%) of these
strains were isolated from patients who did not receive A+C
vaccine, indicating that the individual immune status should
not be a critical factor for developing meningococcal disease
with these serogroup B strains of the A4 lineage rather than
other clonal lineages. Nasopharingeal competition might be an
important factor in the spread of these group B strains, as has
been suggested to explain the spread of serogroup B meningo-
cocci belonging to the ET15 lineage (10). Theoretically, how-
ever, the C:2b strains of the A4 lineage and the B:2b
meningococci also belonging to the A4 lineage should have a
very similar genetic background with the exception of a locus
in the capsular operon (9). In fact, both types of strains showed
not only the same or similar sequence type by MLST but also a
very similar genetic profile by PFGE (data not shown). Thus, a
similar epidemic potential in these two capsular variants might
be expected. Nevertheless, those strains with a group C
polysaccharide capsule maintained a major epidemic even
after a mass immunization campaign (Table 2) and even when
these group C strains were not common in the carrier popula-
tion (14). 
Whether a similar observation can be made for the sero-
group B strains belonging to the A4 clonal lineage is not clear;
the small increase in these serogroup B strains does not appear
to be linked with increased epidemic potential. Thus, the cap-
sular polysaccharide appears to be the only differing factor
between these two types of meningococci. Once again, the
high number of serogroup B strains in asymptomatic carrier
population (14) associated with a natural immunity, might par-
tially explain the different epidemic potential of the two geno-
types. However, the nature of the group C polysaccharide
alone does not explain why C:2b:P1.2,5 strains were responsi-
ble for an important epidemic wave in Spain in 1996–1997.
Some other factors, such as the amount of polysaccharide,
might explain differences in virulence (15).
Two meningococci characterized as B:4:P1.2,5 were
included to analyze if some other antigenic combinations
might appear as result of different genetic events. This possi-
bility was not confirmed in our study but should be more accu-
rately analyzed in the future. 
In 2000, a new increase in cases of group C meningococcal
disease was detected in some regions of Spain (6). Because of
these data, Spanish health authorities made the decision to
include a new group C conjugate vaccine in the routine infant
immunization schedule beginning in autumn 2000. How the
two different vaccines against group C meningococci
Table 1. Distribution and characteristics of B:2b meningococcal 
strains with different antigenic combinations, Spain
Year Identification no.
Antigenic 
expression Pulse type
Clonal lineage 
by MLSTa
1995 9813 B:2b:P1.2,5 NRb ST1380c
9976 B:2b:P1.2,5 PT7 ST8 (A4)
10034 B:2b:P1.2,5 NR ST1489c
1996 10317 B:2b:P1.2,5 PT7 ST8 (A4)
1997 11261 B:2b:P1.2 PT1 ST8 (A4)
11327 B:2b:P1.2,5 PT7 ST8 (A4)
1998 12344 B:2b:P1.2,5 PT7 ST8 (A4)
12366 B:2b:P1.2,5 PT7 ST8 (A4)
1999 12531 B:2b:P1.2 PT8 ST8 (A4)
12644 B:2b:P1.2,5 PT8 ST8 (A4)
12647 B:2b:P1.2,5 PT8 ST8 (A4)
12792 B:2b:P1.2,5 PT8 ST8 (A4)
12367 B:2b:P1.2,5 PT8 ST8 (A4)
2000 13602 B:2b:P1.2 PT38 ST8 (A4)
13818 B:2b:P1.2,5 PT7 ST8 (A4)
13872 B:2b:P1.2,5 PT4 ST66 (A4)
13903 B:2b:P1.2 NR ST162c
14078 B:2b:P1.2,5 PT4 ST66 (A4)
aMLST, multilocus sequence typing.
bNR, pulse types not related to those found in C:2b:P1.2,5 strains.
cClonal lineage not defined.
Table 2. Frequency of the B:2b:P1.2,5 and C:2b:P1.2,5 
meningococcal strains characterized by the laboratory, 1995–2000
Year
No. of strains received by 
the laboratory
No. of C:2b:
P1.2,5 (%)
No. of B:2b:
P1.2,5 (%)
1995 254   56 (22%) 1 (0.4%)
1996 380 176 (46.3%) 1 (0.26%)
1997 687 313 (45.5%) 2 (0.3%)
1998 554 149 (26.9%) 2 (0.36%)
1999 598 144 (24.1%) 5 (0.84%)
2000 502   97 (19.3%) 4 (0.8%)DISPATCHES
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(polysaccharide and conjugate) influence the selection of sero-
group B belonging to the A4 lineage strains in Spain that have
had a capsular-switching event would be an interesting future
topic of research.
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